Integrated Analysis of Mouse and Human Gastric Neoplasms Identifies Conserved microRNA Networks in Gastric Carcinogenesis

Gastroenterology. 2019 Mar;156(4):1127-1139.e8. doi: 10.1053/j.gastro.2018.11.052. Epub 2018 Nov 28.

Abstract

Background & aims: microRNAs (miRNAs) are small noncoding RNAs that bind to the 3' untranslated regions of mRNAs to promote their degradation or block their translation. Mice with disruption of the trefoil factor 1 gene (Tff1) develop gastric neoplasms. We studied these mice to identify conserved miRNA networks involved in gastric carcinogenesis.

Methods: We performed next-generation miRNA sequencing analysis of normal gastric tissues (based on histology) from patients without evidence of gastric neoplasm (n = 64) and from TFF1-knockout mice (n = 22). We validated our findings using 270 normal gastric tissues (including 61 samples from patients without evidence of neoplastic lesions) and 234 gastric tumor tissues from 3 separate cohorts of patients and from mice. We performed molecular and functional assays using cell lines (MKN28, MKN45, STKM2, and AGS cells), gastric organoids, and mice with xenograft tumors.

Results: We identified 117 miRNAs that were significantly deregulated in mouse and human gastric tumor tissues compared with nontumor tissues. We validated changes in levels of 6 miRNAs by quantitative real-time polymerase chain reaction analyses of neoplastic gastric tissues from mice (n = 39) and 3 independent patient cohorts (n = 332 patients total). We found levels of MIR135B-5p, MIR196B-5p, and MIR92A-5p to be increased in tumor tissues, whereas levels of MIR143-3p, MIR204-5p, and MIR133-3p were decreased in tumor tissues. Levels of MIR143-3p were reduced not only in gastric cancer tissues but also in normal tissues adjacent to tumors in humans and low-grade dysplasia in mice. Transgenic expression of MIR143-3p in gastric cancer cell lines reduced their proliferation and restored their sensitivity to cisplatin. AGS cells with stable transgenic expression of MIR143-3p grew more slowly as xenograft tumors in mice than control AGS cells; tumor growth from AGS cells that expressed MIR143-3p, but not control cells, was sensitive to cisplatin. We identified and validated bromodomain containing 2 (BRD2) as a direct target of MIR143-3p; increased levels of BRD2 in gastric tumors was associated with shorter survival times for patients.

Conclusions: In an analysis of miRNA profiles of gastric tumors from mice and human patients, we identified a conserved signature associated with the early stages of gastric tumorigenesis. Strategies to restore MIR143-3p or inhibit BRD2 might be developed for treatment of gastric cancer.

Keywords: Progression; Stomach; Transcription Factor; Tumor Suppressor.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Carcinogenesis / genetics*
  • Case-Control Studies
  • Cell Line, Tumor
  • Cell Proliferation / genetics*
  • Chromosomal Proteins, Non-Histone / metabolism
  • Cisplatin / pharmacology
  • Down-Regulation
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Mice
  • Mice, Knockout
  • MicroRNAs / analysis
  • MicroRNAs / genetics*
  • Neoplasm Transplantation
  • Organoids
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins c-myc / genetics
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / metabolism
  • Survival Rate
  • Transcription Factors
  • Transcription, Genetic / genetics
  • Trefoil Factor-1 / genetics
  • Up-Regulation

Substances

  • Antineoplastic Agents
  • BRD2 protein, human
  • Brd2 protein, mouse
  • Chromosomal Proteins, Non-Histone
  • MIRN143 microRNA, human
  • MYC protein, human
  • MicroRNAs
  • MIRN143 microRNA, mouse
  • Proto-Oncogene Proteins c-myc
  • Tff1 protein, mouse
  • Transcription Factors
  • Trefoil Factor-1
  • Protein Serine-Threonine Kinases
  • Cisplatin